WO2003047634A3 - Nucleic acids and methods for treating ebv-positive cancers - Google Patents

Nucleic acids and methods for treating ebv-positive cancers Download PDF

Info

Publication number
WO2003047634A3
WO2003047634A3 PCT/CA2002/001870 CA0201870W WO03047634A3 WO 2003047634 A3 WO2003047634 A3 WO 2003047634A3 CA 0201870 W CA0201870 W CA 0201870W WO 03047634 A3 WO03047634 A3 WO 03047634A3
Authority
WO
WIPO (PCT)
Prior art keywords
positive cancers
methods
nucleic acids
ebv
gene
Prior art date
Application number
PCT/CA2002/001870
Other languages
French (fr)
Other versions
WO2003047634A2 (en
Inventor
Fei-Fei Liu
Henry Joseph Klamut
Marie Chia
Jian-Hua Li
Original Assignee
Univ Health Network
Fei-Fei Liu
Henry Joseph Klamut
Marie Chia
Jian-Hua Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network, Fei-Fei Liu, Henry Joseph Klamut, Marie Chia, Jian-Hua Li filed Critical Univ Health Network
Priority to AU2002351568A priority Critical patent/AU2002351568A1/en
Publication of WO2003047634A2 publication Critical patent/WO2003047634A2/en
Publication of WO2003047634A3 publication Critical patent/WO2003047634A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is in the area of gene therapy, in particular in the treatment and prevention of EBV-positive cancers by administering a nucleic acid molecule comprising an EBNA1-responsive promoter region operatively linked to a gene necessary for viral replication, preferably in adenovirus replication, and optionally one or more heterologous genes. In embodiments, the one or more heterologous genes comprise a therapeutic gene that can limit tumour cell growth and/or cause the tumour cell to die.
PCT/CA2002/001870 2001-12-06 2002-12-06 Nucleic acids and methods for treating ebv-positive cancers WO2003047634A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002351568A AU2002351568A1 (en) 2001-12-06 2002-12-06 Nucleic acids and methods for treating ebv-positive cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33618001P 2001-12-06 2001-12-06
US60/336,180 2001-12-06

Publications (2)

Publication Number Publication Date
WO2003047634A2 WO2003047634A2 (en) 2003-06-12
WO2003047634A3 true WO2003047634A3 (en) 2004-01-29

Family

ID=23314915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001870 WO2003047634A2 (en) 2001-12-06 2002-12-06 Nucleic acids and methods for treating ebv-positive cancers

Country Status (2)

Country Link
AU (1) AU2002351568A1 (en)
WO (1) WO2003047634A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014101A1 (en) * 1993-11-18 1995-05-26 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses for gene therapy in cancers
WO2002056917A1 (en) * 2001-01-18 2002-07-25 Virgene Biotechnology Limited A recombination virus able to specifically kill tumor associated with eb virus and the constructing method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014101A1 (en) * 1993-11-18 1995-05-26 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses for gene therapy in cancers
WO2002056917A1 (en) * 2001-01-18 2002-07-25 Virgene Biotechnology Limited A recombination virus able to specifically kill tumor associated with eb virus and the constructing method thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"EFFICACY OF IONIZING RADIATION COMBINED WITH ADENOVIRAL P53 THERAPY IN EBV-POSITIVE NASOPHARYNGEAL CARCINOMA", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 87, no. 4, 15 August 2000 (2000-08-15), pages 606 - 610, XP001145455, ISSN: 0020-7136 *
CHIA, M.C. ET AL.: "A novel conditionally oncolytic adenovirus for the treatment of nasopharyngeal carcinoma (NPC)", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 1098 - 1099, XP001147482 *
DATABASE WPI Derwent World Patents Index; AN 2002-566772, XP002242870, CHE, X. ET AL.: "Construction of reproductive recombination virus able to specifically kill Epstein-Barr associated tumor cells, useful in drugs for treating e.g. nasopharyngeal cancer, Hodgkin's lymphoma and gastric cancer" *
HALLENBECK, P.L. ET AL.: "A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma", HUMAN GENE THERAPY, vol. 10, 1 July 1999 (1999-07-01), pages 1721 - 1733, XP002242915 *
HERNANDEZ-ALCOCEBA, R. ET AL.: "A novel, conditionally replicative adenovirus for th4 treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors", HUMAN GENE THERAPY, vol. 11, 20 September 2000 (2000-09-20), pages 2009 - 2024, XP001152711 *
JUDDE, J.-G. ET AL.: "Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia", HUMAN GENE THERAPY, vol. 7, 20 March 1996 (1996-03-20), pages 647 - 653, XP009010762 *
KURIHARA, T. ET AL.: "Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressiong the MUC1 antigen", JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 6, September 2000 (2000-09-01), pages 763 - 771, XP002242916 *

Also Published As

Publication number Publication date
AU2002351568A1 (en) 2003-06-17
AU2002351568A8 (en) 2003-06-17
WO2003047634A2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
CA2293612A1 (en) Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor
DE69636032D1 (en) PLASMIDE FOR THE ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO2022195074A3 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
DE60027870D1 (en) GENETIC MANIPULATED HERPESVIRUS FOR THE TREATMENT OF TUMORS
WO1999038964A3 (en) Promoter regions of the mouse and human telomerase rna component genes
DE69635349D1 (en) NUCLEOTIDE SEQUENCES, PROTEINS, MEDICAMENTS AND DIAGNOSIS AGENTS FOR THE USE OF CANCER TREATMENT
IL107250A0 (en) Tumor supressor gene, protein encoded thereby and use of said gene and protein
EP1070122A4 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
MXPA05010575A (en) Peptabody for cancer treatment.
WO2002045737A3 (en) Methods of treatment involving human mda-7
DE60129069D1 (en) Hepatitis B virus vectors for gene therapy
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy
HUP0100776A2 (en) Self-regulated apoptosis of inflammatory cells by gene therapy
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2006026451A3 (en) Targeted expression of apoptosis-inducing genes for disease treatment
WO1999042137A3 (en) Stress promoter control of therapeutic genes in gene therapy: compositions and methods
WO2001055410A3 (en) Ceramidase compositions and methods based thereon
WO2005074605A3 (en) Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
WO2004096826A3 (en) Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
WO2020234498A3 (en) Gene therapy with the genes hokd and ldrb for cancer treatments
WO2001024832A3 (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP